Literature DB >> 1894376

Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.

N Moayeri1, C M Collins, P O'Hanley.   

Abstract

A BALB/c mouse model of nonobstructive, ascending Proteus mirabilis pyelonephritis was characterized bacteriologically, histologically, and serologically from 3 to 28 days. Intravesicular administration of 2 X 10(8) P. mirabilis K7 resulted in the septic death of 9 (16%) of 57 mice by day 15. Among the survivors, K7 colonized the kidneys in great numbers until day 21. Histological examination of the kidneys revealed acute inflammation which was characterized by neutrophil infiltration by day 3, renal necrosis by day 7, and fibroblastic infiltration by day 14 which persisted at least until day 28. The immunoglobulin G response to the outer membrane proteins (OMP) was assessed by enzyme-linked immunosorbent assay and Western blotting (immunoblotting). Anti-OMP immunoglobulin G antibodies were detected as early as day 7, and the reciprocals of their titers rose progressively up to day 28 (i.e., greater than or equal to 500). This model was also used to assess the efficacy of OMP and lipopolysaccharide (LPS) immunization in preventing renal infection. K7 OMP or LPS (100 micrograms) preparations were administered intramuscularly in Freund's complete adjuvant. After 2 weeks, mice were intravesicularly challenged with 2 X 10(8) bacteria of the homologous K7 strain or one of four heterologous strains. Compared with the saline-immunized control group and K7 LPS-immunized mice, K7 OMP recipients were protected from death when challenged by homologous or heterologous strains. In addition, K7 OMP recipients were protected (P less than 0.003) from subsequent renal infection when challenged by the K7 strain and had more rapid bacterial renal clearance when challenged by three of four heterologous strains. OMP recipients produced antibodies which bound major OMP moieties (viz., 36- to 39-kDa cell wall constituents) as assessed by Western blotting. These results support the concept that immunization with selected bacterial protein surface coat constituents can prevent uromucosal infection by interfering with colonization or renal injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894376      PMCID: PMC258951          DOI: 10.1128/iai.59.10.3778-3786.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Nosocomial infections in a long-term care facility.

Authors:  M H Magnussen; S S Robb
Journal:  Am J Infect Control       Date:  1980-02       Impact factor: 2.918

Review 2.  Microbial ureases: significance, regulation, and molecular characterization.

Authors:  H L Mobley; R P Hausinger
Journal:  Microbiol Rev       Date:  1989-03

3.  Immunoadsorbent-purified antibodies in the study of antigenic relatedness of outer membrane proteins of enteric bacilli.

Authors:  A Z Henriksen; J A Maeland
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1986-08

4.  Protective immunity induced by outer membrane proteins of Salmonella typhimurium in mice.

Authors:  V Udhayakumar; V R Muthukkaruppan
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

5.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

6.  Cytotoxic activity of the Proteus hemolysin HpmA.

Authors:  K G Swihart; R A Welch
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  The HpmA hemolysin is more common than HlyA among Proteus isolates.

Authors:  K G Swihart; R A Welch
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Proteus mirabilis strains of diverse type have IgA protease activity.

Authors:  B W Senior; M Albrechtsen; M A Kerr
Journal:  J Med Microbiol       Date:  1987-09       Impact factor: 2.472

9.  Identification of two different hemolysin determinants in uropathogenic Proteus isolates.

Authors:  R A Welch
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

10.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide.

Authors:  C Moreno; M R Lifely; J Esdaile
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

View more
  12 in total

Review 1.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 2.  Potential virulence factors of Proteus bacilli.

Authors:  A Rózalski; Z Sidorczyk; K Kotełko
Journal:  Microbiol Mol Biol Rev       Date:  1997-03       Impact factor: 11.056

3.  Analysis of inflammatory cytokine expression in the urinary tract of BALB/c mice infected with Proteus (P.) mirabilis and enteroaggregative Escherichia (E.) coli (EAEC) strains.

Authors:  Araceli Melendez-Avalos; Teresita Sainz-Espuñes; Laura Estela Castrillón-Rivera; Felipe Mendoza-Pérez; Alejandro Palma-Ramos; Jorge Ismael Castañeda-Sánchez; Elisa Maria Drago-Serrano
Journal:  Folia Microbiol (Praha)       Date:  2019-05-19       Impact factor: 2.099

4.  Adhesion, invasion, and agglutination mediated by two trimeric autotransporters in the human uropathogen Proteus mirabilis.

Authors:  Praveen Alamuri; Martin Löwer; Jan A Hiss; Stephanie D Himpsl; Gisbert Schneider; Harry L T Mobley
Journal:  Infect Immun       Date:  2010-08-30       Impact factor: 3.441

5.  Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; C Virginia Lockatell; David E Johnson; M Chelsea Lane; John W Warren; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

Review 7.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

8.  Ability of Proteus mirabilis to invade human urothelial cells is coupled to motility and swarming differentiation.

Authors:  C Allison; N Coleman; P L Jones; C Hughes
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 9.  Proteus mirabilis and Urinary Tract Infections.

Authors:  Jessica N Schaffer; Melanie M Pearson
Journal:  Microbiol Spectr       Date:  2015-10

10.  Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.

Authors:  Praveen Alamuri; Kathryn A Eaton; Stephanie D Himpsl; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-11-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.